-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6

Benzinga·11/12/2026 13:38:37
Listen to the news
Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and raises the price target from $3 to $6.